Seulki Kim
0000-0001-5505-1022
3 papers found
Refreshing results…
A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
Significance of 18F-FDG PET parameters according to histologic subtype in the treatment outcome of stage III non-small cell lung cancer undergoing definitive concurrent chemoradiotherapy
Missing publications? Search for publications with a matching author name.